USFDA completes inspection of Lupin’s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations”.

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.

  • Related Posts

    8 Women Develop Complications Post C-Section, 2 Critical

    Close on the heels of maternal deaths and kidney-related complications reported in Kota and Bikaner following caesarean deliveries, a similar case has surfaced at Paota District Hospital in Jodhpur, where…

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Jaipur/Kota— In a significant move to strengthen patient safety and improve healthcare delivery in government hospitals, Kota district in-charge secretary Dr. Ravi Kumar Surpur has directed the immediate preparation and effective…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    8 Women Develop Complications Post C-Section, 2 Critical

    8 Women Develop Complications Post C-Section, 2 Critical

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Probe report into maternal deaths sparks Kota row

    Probe report into maternal deaths sparks Kota row

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    CDSCO constitutes consultancy committee for advice on suo motu disclosure

    CDSCO constitutes consultancy committee for advice on suo motu disclosure